Hirsutism;Hirsutisme

Revue Medicale Suisse

Volumn 1, Issue 6, 2005, Pages 420-424

  Rouiller, Dominique G ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; CYCLOSPORIN A; DANAZOL; DIAZOXIDE; GESTAGEN; HYDROCORTISONE; METHYLDOPA; METOCLOPRAMIDE; MINOXIDIL; PENICILLAMINE; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PRASTERONE; PSORALEN DERIVATIVE; RESERPINE; STREPTOMYCIN; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ANOVULATION; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ENZYME INHIBITION; GONADAL DISEASE; HAIR FOLLICLE; HIRSUTISM; HORMONE SENSITIVITY; HUMAN; HYPERTRICHOSIS; INSULIN SENSITIVITY; MORBIDITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; RECEPTOR BLOCKING; REVIEW; TREATMENT PLANNING; CONGENITAL ADRENAL HYPERPLASIA; FEMALE; GENETICS; HYPERANDROGENISM; OVARY TUMOR;

ADRENAL HYPERPLASIA, CONGENITAL; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; OVARIAN NEOPLASMS; POLYCYSTIC OVARY SYNDROME;

EID: 17844369167     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Ferriman D, JD Gallwey. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
2. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: Implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30.
3. http://www.aly-abbara.com/echographie/biometrie/scores/ scoreferrimangallwey.html
4. Carmina ET, Koyama L, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1992;167:1807-12.
5. Azziz RL, Sanchez A, Knochenhauer ES, et al. Boots. Extensive personal experience: Androgen excess In women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453-62.
6. Kalsas GA, Isidori AM, Kola BP, et al. The Value of the Low-Dose Dexamethasone Suppression Test in the Differential Diagnosis of Hyperandrogenism in Women. J Clin Endocrinol Metab 2003;88:2634-43.
7. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003;4:CD001125.
8. Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990;70:642-6.
9. Breitkopf DM, Rosena MP, Youngb SL, Nagamania M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 2003;67:349-53.
10. Pazos F, Escobar-Morreale H, Balsa J, Sancho JM, Varela C. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122-8.
11. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 2003;79:942-6.
12. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116-23.
13. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androge abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reproduction 2003;18:1210-8.
14. Shenenberger DW, Utecht LM. Removal of unwanted facial hair. Am Fam Physician 2002;66:1907-11, 1913-4.
15. Hickman JG, Huber F, Palmisano M. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. Curr Med Res Opin 2001;16:235-44.
16. Pour les amateurs d'algorithmes: Hunter MH, et Carek PJ. Evaluation and treatment of women with hirsutism. Am Fam Physician 2003;67:2565-72.